Food and Drug Administration
May 14, 2003
The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.
Suppressive Therapy With Valtrex® (valacyclovir HCI) Caplets to Reduce the Frequency of Transmission of Genital Herpes, GlaxoSmithKline (PDF)